^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    plocabulin (PM184)

    i
    Other names: PM184, PM-184, PM 060184, PM-60184, PM060184
    Company:
    PharmaMar
    Drug class:
    Microtubule inhibitor, Tubulin binding agent
    Related drugs:
    2years
    From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds. (PubMed, Front Pharmacol)
    The main marine-derived drugs that have been studied for the treatment of BC are tubulin-binding agents (eribulin and plocabulin), DNA-targeting agents (cytarabine and minor groove binders-trabectedin and lurbinectedin) and Antibody-Drug Conjugates (ADCs)...Among these, clinical data are available on ladiratuzumab vedotin and glembatumumab vedotin in TNBC, and on disitamab vedotin and ALT-P7 in HER2-positive patients. A deeper knowledge of the mechanism of action and of the potential predictive factors for response to marine-derived drugs is important for their rational and effective use, alone or in combination. In this narrative review, we discuss the role of marine-derived drugs for the treatment of BC, although most of them are not approved, and the opportunities that could arise from the potential treasure trove of the sea for novel BC therapeutics.
    Review • Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
    |
    HER-2 positive • BRCA mutation
    |
    cytarabine • Halaven (eribulin mesylate) • Aidixi (disitamab vedotin) • Yondelis (trabectedin) • Zepzelca (lurbinectedin) • glembatumumab vedotin (CDX-011) • plocabulin (PM184) • ALT-P7 • ladiratuzumab vedotin (SGN-LIV1A)